PDCD1 and melanoma: In addition, we found that patients with thyroid dysfunction and skin toxicity had a better prognosis, which is also consistent with previous meta-analysis for non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC) treated with anti-PD-1 antibody or anti-CTLA-4 antibody [18].